

21 **Abstract**

22 3D printed alternatives to standard flocked swabs were rapidly developed to provide a response to
23 the unprecedented and sudden need for an exponentially growing amounts of diagnostic tools to
24 fight the pandemics of COVID-19. In light of the anticipated shortage, an hospital-based 3D
25 printing platform was implemented in our institution for the production of swabs for
26 nasopharyngeal and oropharyngeal sampling based on the freely available open-sourced design
27 made available to the community by University of South Florida’s Health Radiology and
28 Northwell Health System teams as replacement for locally used commercial swabs. Validation of
29 our 3D printed swabs was performed by a head-to-head diagnostic accuracy study of the 3D printed
30 “Northwell model” with the cobas PCR Media swabs sample kit. We observed an excellent
31 concordance (total agreement 96.8%, Kappa 0.936) in results obtained with the 3D printed and
32 flocked swabs indicating that the in-house 3D printed swab can be used reliably in a context of
33 shortage of flocked swabs. To our knowledge, this is the first study to report on autonomous
34 hospital-based production and clinical validation of 3D printed swabs.

35

36 **Introduction**

37 In December 2019, the outbreak of an atypical severe respiratory syndrome, now known as
38 coronavirus 19 disease (COVID-19) in Wuhan, China (1), rapidly led to the identification of the
39 Severe acute respiratory syndrome (SARS)-Coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is highly
40 transmissible (2, 3) and its rapid spread throughout the world led the World Health Organization
41 to declare the COVID-19 outbreak a global pandemic on March 11th 2020 (4). This triggered an
42 unprecedented and sudden need for an exponentially growing amount of personal protection
43 equipment and diagnostic tools. Real-time Polymerase Chain Reaction (PCR)-based detection of
44 SARS-CoV-2 nucleic acids has rapidly become the gold standard to diagnose patients infected
45 with SARS-CoV-2 (5). As typically performed for the detection of respiratory viruses, accurate
46 COVID-19 PCR assay relies on the collection of samples from the upper respiratory tract including
47 nasopharyngeal (NP) and oral mucosal surfaces (6). Flocked swabs feature perpendicular fibers
48 that optimize specimen collection and elution in transport media and are hence considered optimal
49 for sampling the respiratory tract mucosal surfaces. As testing rapidly became critical for the
50 development of a COVID-19 response strategy, the world encountered shortage of PCR reagents
51 and sampling swabs, resulting in testing backlogs, delayed diagnosis, compromised contact tracing
52 and quarantine of patients and, potentially increased disease transmission.

53

54 The versatility of 3D-printing as well as the possibility of rapidly developing prototypes have
55 enabled rapid mobilization of this technology to provide a response to the interruption of supply
56 chains (7, 8). 3D printed alternatives to standard flocked swabs were rapidly developed. Early in
57 the pandemic, open-sourced design for 3D printed swabs, were generously made available to the

58 community by the teams from University of South Florida's (USF) Health Radiology and
59 Northwell Health System (9, 10). The design and workflow for hospital-based printing was
60 subsequently published (8). Local manufacturing based on 3D printing is among the strategies that
61 can help alleviate supply chain shortages.

62
63 In light of the anticipated shortage of sampling swabs in our hospital and in the province of Quebec,
64 we sought to locally manufacture and evaluate sterile 3D printed swabs based on the freely
65 available open source designs as replacement for locally used commercial swabs (8). Here, we
66 report on the fabrication process and clinical evaluation of the 3D printed swabs against the cobas
67 PCR Media® swab sample kit in a prospective cohort of symptomatic healthcare workers. To our
68 knowledge, this is the first study to report on autonomous hospital-based production and evaluation
69 of 3D printed swabs. Our study showed that our locally printed swabs were a reliable alternative
70 to commercial swabs and confirmed the initial assumption made by the USF and Northwell Health
71 system groups that hospital-based production of 3D printed swabs can constitute a rapid, on-
72 demand local response to provide replacements for pandemic-related disruption of the swabs
73 supply chains.

74

75 **METHODS**

76 **3D printing**

77 3D prototypes of swabs were designed and shared by teams from the Division of 3D Clinical
78 Applications at USF and Northwell Health system (8). All final printed models successfully passed

79 a complete set of mechanical tests (11). In our hospital-based production, we used the model
80 referred to as “Northwell model” to which a breaking point located at 80 mm from the tip was
81 added to the original design.

82 Swabs were printed by stereolithography (SLA) using Formlabs Form 3 and 3B printers
83 (Formlabs, Somerville, Massachusetts, USA) with Surgical Guide resin (Formlabs, Cat#RS-F2-
84 SGAM-01) that is biocompatible and sterilizable. The Preform software (Formlabs) was used to
85 create an array of 256 swab models to be converted into printer instructions. The thickness of each
86 printed layer was set to 0.1 mm. Printed swabs were cleaned in 99% isopropyl alcohol (IPA)
87 (Sigma Aldrich, Cat#PX1835-3) for 20 minutes using the Form Wash (Formlabs) station and
88 allowed to air dry for at least 30 minutes before being post-cured at 70°C for 30 minutes in a Form
89 Cure (Formlabs) station. Visual inspection was performed to verify that printed swabs were free
90 of defects, otherwise they were discarded.

91

92 **Sterilization**

93 At the end of the production procedure, 3D printed swabs were immediately individually packed
94 in autoclavable flat pouches (4 in × 10.5 in, Stevens Company, #164-S5) previously identified with
95 autoclave-resistant laser labels (GA International, #AKA-13) indicating the swabs assigned lot
96 number and date of production. Pouches were sealed with a vacuum rotosealer machine (Wipak
97 Medical, #RS120). Appropriate sealing was verified visually. Sterilization was performed by
98 autoclaving using a pre-vacuum steam cycle set at 132°C (270°F) for 4 min followed by a 30 min
99 drying period.

100 To verify the efficacy of the sterilization procedure for each lot, the head of two swabs per
101 production lot were inoculated with 10 μ L of the Biological Indicator *Geobacillus*
102 *stearothermophilus* spore suspension (1.7×10^7 CFU/0.1 mL; Steris Corporation, #NA-091) under
103 sterile conditions (12). Inoculated swabs were held horizontally for 30min and further let dry
104 vertically for 24 h under sterile conditions. Next, dried swabs were sealed individually in
105 sterilization pouches. One of the inoculated swabs was subjected to sterilization as described
106 above, together with all swabs from the same lot. The other inoculated swab was kept in the pouch
107 and was not sterilized. The two inoculated swabs were broken at the breakpoint and inserted into
108 a bacteriology tube (Sarstedt, #62515006) containing 5 mL of tryptic soy broth culture media
109 (Sigma Aldrich, #1463170010). Bacteria growth was monitored by incubation at 55°C with orbital
110 agitation for 7 days. A culture media only negative control was also used. OD600nm was measured
111 on day 7 to assess bacterial growth.

112

113 **Quality control**

114 Swabs showing excessive warping post-sterilization were discarded after visual inspection. Basic
115 mechanical testing was performed using a guide formed by 3 semicircular canals with a minimum
116 radius of 15, 25 and 35 mm, respectively, that allowed testing the flexibility of swabs. The test
117 was successful if the head and neck remained intact after going through each canal. The final test
118 consisted in breaking the swab in half with one hand at its breaking point.

119

120

121 **3D swabs clinical evaluation study participants' recruitment**

122 This study was performed in our institution's COVID-19 rapid screening clinic and included
123 symptomatic healthcare workers self-presenting for COVID-19 diagnostic testing. During an
124 initial recruitment phase, participants were tested simultaneously with both the cobas PCR Media®
125 swab sample kit (Roche Diagnostics, Laval, Quebec, Canada) and the 3D printed swabs. As for
126 any COVID-19 test, all results were transmitted to the institution occupational health and safety
127 office and public health authorities. In a subsequent recruitment phase, to increase the number of
128 positive samples within the study, patients having previously tested positive on routine testing
129 were contacted by clinical research personnel and offered to participate in the study. For those
130 participants, both sampling techniques were repeated simultaneously.

131

132 **Oro-nasopharyngeal swab collection and SARS-CoV-2 PCR testing**

133 A sequential oropharyngeal and nasopharyngeal sampling with each single swab was performed.
134 For the nasopharyngeal sampling, Cobas PCR Media swabs sample kit and 3D printed swab were
135 used in the same nostril in a randomized order. The swabs were transferred separately to tubes
136 containing the cobas PCR Media transport medium before proceeding with the PCR analysis. All
137 samples were tested on the FDA emergency use authorization (EUA) approved and locally
138 validated cobas 8800 automated RT-PCR system which simultaneously tests the *ORF1 a/b* and *E-*
139 gene viral molecular targets together with an internal control (13).

140 In conclusion, our study adds to the few clinical validation studies that demonstrated safety and
141 accuracy of 3D swabs. Our study is unique in that it tested a fully integrated hospital-based

142 production of 3D-printed swabs as initially suggested by the USF and Northwell Health system
143 groups. Our clinical trial has demonstrated that our local 3D printed swab production line offers a
144 reliable local alternative to commercial swabs and therefore confirms that it is a viable local
145 response to provide replacements in the event of pandemic supply chain disruption.

146 **Statistical analysis**

147 The Lilliefors statistical test adapted from the Kolmogorov–Smirnov nonparametric test was used
148 to assess data distribution normality. The Wilcoxon matched-pairs test for non-normal
149 distributions was used to evaluate the difference between means of RT-PCR cycle thresholds (Ct)
150 obtained following both sampling methods. Concordance analysis between both assays using
151 overall, positive and negative agreement percentages was performed with calculation of the
152 Cohen's Kappa values. By definition, Kappa values above 0.75 indicate excellent agreement,
153 values between 0.40 and 0.75 indicate fair to good agreement, and values below 0.40 represent
154 poor agreement beyond chance (14). Results obtained with the cobas PCR Media® swabs sample
155 kit were considered as reference for positive and negative agreement calculation purposes.

156

157 **Ethical approval**

158 The study received ethical approval from the Comité d'éthique de la Recherche of the Centre de
159 Recherche du Centre Hospitalier de l'Université de Montréal (CHUM, 2021-9015 / 20.079). All
160 participants were provided written informed consent.

161

162

163 **RESULTS**

164

165 **3D printed swab model**

166 In a pilot print to start implementing a hospital production of 3D printed swabs, a biocompatible
167 and sterilizable surgical guide resin to print two models from the designs shared by the 3D Clinical
168 Applications Division of the USF and Northwell Health System was used. The two printed models
169 are referred to as "USF" and "Northwell" (8). Based on the flexibility and the smaller head size,
170 the "Northwell model" was selected by the clinical diagnostic team to pursue with the clinical
171 tests. The cattail design of the "Northwell" model is composed of a head (18.0 mm long and 3.3
172 mm in diameter), a flexible neck (56.0 mm; 1.2 mm) and a handle (77.0 mm; 2.6 mm). Based on
173 this pilot evaluation, a breaking point (1.0 mm; 1.4 mm) located at 80 mm from the tip to the
174 original design was added to facilitate the release of the swab head in the transport tube containing
175 the transport medium (**Figure 1A-C**). Three separate lots of 256 swabs were printed to ensure
176 reproducibility of the production process and of the subsequent clinical evaluation. Swabs were
177 packed individually in sterilization pouches before autoclaving (**Figure 1D**). Efficiency of the
178 sterilization was verified for each lot through inhibition of *Geobacillus stearothermophilus* spore
179 suspension inoculated on the head of one swab per lot (**Figure 2**). Two swabs from each printed
180 lot were subjected to quality control check including testing of the flexibility (**Figure 1E**) and
181 breaking of the swabs at the breaking point.

182

183 **Clinical testing**

184 A total of 63 participants were enrolled in the study. Thirty-two participants tested negative and
185 31 tested positive with the cobas 8800 SARS-CoV-2 PCR. Swabs from the 3 distinct printed lots

186 were used for sample collection (batch 1, n = 21, 11 positives, 10 negatives; batch 2, n = 21, 11
187 positives; 10 negatives; batch 3, n = 21, 9 positives, 12 negatives). Lilliefors statistical test and
188 Kolmogorov–Smirnov nonparametric test showed that cycle threshold (Ct) distributions for both
189 swabs were not standard (p=0.12). PCR results for the *E*-gene (p=0.27), *ORF1* gene (p=0.92) and
190 internal control (p=0.59) did not show significant Ct differences between flocked swabs and 3D
191 printed swabs (**Figure 3 and Table 1**). A full agreement table between the flocked and the 3D
192 printed swabs is presented in **Table 2A**. Overall, positive and negative agreements were
193 respectively 96.8% (61/63), 96.9% (31/32) and 96.8% (30/31) with a Kappa value of 0.936 (**Table**
194 **2B**). In 2 cases, results obtained with the 2 swabs were discordant. In one case the flocked swab
195 sample was positive with a Ct of 37.3 for the *E* gene only. For this same participant, the sample
196 obtained with the 3D printed swab led to no amplification for both genes. In the second discordant
197 case, the flocked swab sample was negative for both genes, while the 3D printed swab result was
198 positive for both *ORF1* (Ct = 33.2) and *E* (Ct = 38.1) targets. Although, in both discordant cases
199 the detected Ct were high, several other samples included in this study also had Ct in the high
200 range without showing discordant results.

201

202 **DISCUSSION**

203 In this report, we described the implementation of a hospital-based 3D printing platform for the
204 production of swabs for nasopharyngeal and oropharyngeal sampling for COVID-19 diagnosis.
205 Such swabs are classified as Class I medical devices under the Canadian regulatory framework of
206 Health Canada. To validate our 3D printed swabs, we performed a head-to-head diagnostic
207 accuracy study of the 3D printed “Northwell model” swab (8) with the cobas PCR Media swabs
208 sample kit. We observed a high concordance (total agreement 96.8%, Kappa 0.936) in results

209 obtained with the 3D printed and flocked swabs indicating that the in-house 3D printed “Northwell
210 model” swab can be used reliably in a context of shortage of flocked swabs. Previous clinical trial
211 performed by the USF and Northwell Health System teams have reached similar conclusions by
212 comparing the 3D printed “USF model” swab with standard flocked swabs using alternative
213 transport medium, including the World Health Organization (WHO) approved viral transport
214 media, media produced in-house according to the procedure described by the Centers for Disease
215 Control and Prevention (CDC) or commercially available Universal Transport Media (10). At the
216 time of starting our clinical trial, our hospital was not facing a shortage of supply, or planning to
217 be out of stock in the medium term, of swabs for the diagnosis of COVID-19. Therefore, we were
218 able to use the transport medium provided in the cobas PCR Media swabs sample kit with the 3D
219 printed swab to ensure consistency in the clinical evaluation. The RT-PCR was performed through
220 the trial on a single local cobas 8800 automated RT-PCR system authorized by Health Canada
221 under an interim order for use related to COVID-19 diagnosis after complete published validation
222 of the assay (13, 15). Given the complexity and discomfort associated with repeated simultaneous
223 nasopharyngeal testing and the necessity to validate the use of 3D printed swab in a controlled
224 head-to-head approach, we did not include other transport media in our validation study. We did
225 not observe significant Ct values differences between swabs for the *ORF1* and *E* SARS-CoV-2
226 genes in the Roche cobas assay. These observations are in agreement with the data from the clinical
227 trial performed by the USF and Northwell system teams using the 3D printed “USF model” swab
228 compared to the Roche cobas sampling kit (97.03% agreement, Kappa 0.863) (10). In a study
229 comparing swabs from four distinct 3D-printing manufacturers to the Copan swab (501CS01)
230 using a RT-PCR run on a Abbott m2000 RealTime system platform, high degree of concordance
231 with Kappa values between [0.85-0.89] were observed (16). An additional prospective clinical

232 validation compared 3D-printed swabs from two manufacturers with the Universal Viral Transport
233 Kit by Becton, Dickinson & Company using a liaison MDX RT-PCR machine (DiaSorin
234 Molecular, LLC) and the Simplexa COVID-19 Direct Kit. Again, an excellent concordance
235 between sampling procedures was observed (17).

236

237 To our knowledge, this is the first study reporting on autonomous hospital-based production and
238 evaluation of 3D printed swabs. The implementation of our hospital-based platform was facilitated
239 by the existing “Health-related 3D printing centre” in our institution, which normally serves the
240 needs of the Radiation Oncology department and other hospital sectors, but quickly reoriented its
241 efforts to provide healthcare workers with the much-needed protection equipment and diagnostic
242 tools. Additionally, we had access to an institutional sterilization service that allowed us to easily
243 perform the steam sterilization that was chosen as a rapid, nontoxic and inexpensive technique that
244 is microbicidal and sporicidal, and was previously shown to be compatible with the Surgical Guide
245 resin (18). Actual installations and staff availability allowed us to limit the production costs of 3D
246 printed swabs. The total cost per swab was about 0.56USD, which included 0.26USD for
247 consumables and 0.29USD for staff wages. Further optimization has yet to be realized to increase
248 the production volume and lower the production costs.

249

250 In conclusion, our study adds to the few clinical validation studies that demonstrated safety and
251 accuracy of 3D swabs. Our study is unique in that it tested a fully integrated hospital-based
252 production of 3D-printed swabs as initially suggested by the USF and Northwell Health system
253 groups. Our clinical trial has demonstrated that our local 3D printed swab production line offers a
254 reliable local alternative to commercial swabs and therefore confirms that it is a viable local

255 response to provide replacements in the event of pandemic supply chain disruption. In-house
256 production of 3D printed swabs option remains particularly relevant as the need for testing capacity
257 continues to increase across the world, as many countries are experiencing new waves of infection
258 with the emergence of variants of SARS-CoV-2 (19, 20). Our experience in the rapid
259 implementation of this production line could serve as an example for other institutions around the
260 world in the fight against COVID-19.

261

262 **ACKNOWLEDGEMENT**

263 The authors thank Floriane Point and Stephanie Matte for help with the ethics approval and
264 organization of patient recruitment. The authors thank all the patients who generously accepted to
265 participate in this study and the laboratory technicians involved in this project. This study was
266 funded by the Fondation du Centre Hospitalier de l'Université de Montréal. The funder had no
267 role in the study design, data collection and interpretation, or the decision to submit the work for
268 publication. SGL has received funding from Roche Diagnosis to test PCR Medium stability. FC
269 received grants paid to the organization for research projects unrelated to the present study from
270 Roche Diagnostics and Merck Sharp and Dome, honorariums for presentations from Merck Sharp
271 and Dome and Roche diagnostics, and has participated in an expert vaccine group by Merck Sharp
272 and Dome.

273

274 **REFERENCES**

275

- 276 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P,
277 Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W. 2020. A Novel Coronavirus from

- 278 Patients with Pneumonia in China, 2019. *The New England Journal of Medicine* 382:727-
279 733.
- 280 2. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. 2020. The Novel
281 Coronavirus, 2019-nCoV, is Highly Contagious and More Infectious Than Initially
282 Estimated. medRxiv:2020.02.07.20021154.
- 283 3. Zheng J. 2020. SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat.
284 *International journal of biological sciences* 16:1678-1685.
- 285 4. Organization WH. 11 March 2020 2020. WHO Director-General's opening remarks at the
286 media briefing on COVID-19 - 11 March 2020, *on* World Health Organization.
287 [https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-
288 remarks-at-the-media-briefing-on-covid-19---11-march-2020](https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020). Accessed
- 289 5. Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M, Dittrich S,
290 Yansouni CP. 2020. Diagnostic Testing for Severe Acute Respiratory Syndrome-Related
291 Coronavirus 2: A Narrative Review. *Ann Intern Med* 172:726-734.
- 292 6. Wang H, Liu Q, Hu J, Zhou M, Yu MQ, Li KY, Xu D, Xiao Y, Yang JY, Lu YJ, Wang F,
293 Yin P, Xu SY. 2020. Nasopharyngeal Swabs Are More Sensitive Than Oropharyngeal
294 Swabs for COVID-19 Diagnosis and Monitoring the SARS-CoV-2 Load. *Front Med*
295 (Lausanne) 7:334.
- 296 7. Choong YYC, Tan HW, Patel DC, Choong WTN, Chen C-H, Low HY, Tan MJ, Patel CD,
297 Chua CK. 2020. The global rise of 3D printing during the COVID-19 pandemic. *Nature*
298 *Reviews Materials* 5:637-639.
- 299 8. Ford J, Goldstein T, Trahan S, Neuwirth A, Tatoris K, Decker S. 2020. A 3D-printed
300 nasopharyngeal swab for COVID-19 diagnostic testing. *3D Printing in Medicine* 6:21.

- 301 9. Rybicki FJ. 2020. 3D Printing in Medicine: COVID-19 Testing with 3D Printed
302 Nasopharyngeal Swabs. Clin Infect Dis ciaa1437.
- 303 10. Decker SJ, Goldstein TA, Ford JM, Teng MN, Pugliese RS, Berry GJ, Pettengill M, Silbert
304 S, Hazelton TR, Wilson JW, Shine K, Wang ZX, Hutchinson M, Castagnaro J, Bloom OE,
305 Breining DA, Goldsmith BM, Sinnott JT, O'Donnell DG, Crawford JM, Lockwood CJ,
306 Kim K. 2020. 3D Printed Alternative to the Standard Synthetic Flocked Nasopharyngeal
307 Swabs Used for COVID-19 testing. Clin Infect Dis ciaa1366.
- 308 11. Spadaccini C, Duoss E, Shusteff M, Tooker A, Haque R. 2020. Swab Tensile Testing
309 Results and Procedures. USDOE National Nuclear Security Administration (NNSA)
310 LLNL-TR-808538 1014512.
- 311 12. Albert H, Davies DJ, Woodson LP, Soper CJ. 1998. Biological indicators for steam
312 sterilization: characterization of a rapid biological indicator utilizing *Bacillus*
313 *stearothermophilus* spore-associated alpha-glucosidase enzyme. J Appl Microbiol 85:865-
314 74.
- 315 13. Boutin CA, Grandjean-Lapierre S, Gagnon S, Labbé AC, Charest H, Roger M, Coullée F.
316 2020. Comparison of SARS-CoV-2 detection from combined
317 nasopharyngeal/oropharyngeal swab samples by a laboratory-developed real-time RT-
318 PCR test and the Roche SARS-CoV-2 assay on a cobas 8800 instrument. J Clin Virol
319 132:104615.
- 320 14. Fleiss JL. 1981. Statistical Methods for Rates and Proportions. Second Edition. Wiley, John
321 and Sons, Incorporated, New York, N.Y.
- 322 15. Canada H. 18 March 2020 2020. Health Canada expedites access to COVID-19 diagnostic
323 laboratory test kits and other medical devices, *on* Health Canada.

- 324 <https://www.canada.ca/en/health-canada/news/2020/03/health-canada-expedites-access->
325 [to-covid-19-diagnostic-laboratory-test-kits-and-other-medical-devices.html](https://www.canada.ca/en/health-canada/news/2020/03/health-canada-expedites-access-to-covid-19-diagnostic-laboratory-test-kits-and-other-medical-devices.html). Accessed
- 326 16. Callahan CJ, Lee R, Zulauf KE, Tamburello L, Smith KP, Previtera J, Cheng A, Green A,
327 Abdul Azim A, Yano A, Doraiswami N, Kirby JE, Arnaout RA. 2020. Open Development
328 and Clinical Validation of Multiple 3D-Printed Nasopharyngeal Collection Swabs: Rapid
329 Resolution of a Critical COVID-19 Testing Bottleneck. *J Clin Microbiol* 58:e00876-20.
- 330 17. Oland G, Garner O, de St Maurice A. 2021. Prospective clinical validation of 3D printed
331 nasopharyngeal swabs for diagnosis of COVID-19. *Diagn Microbiol Infect Dis* 99:115257.
- 332 18. Sharma N, Cao S, Msallem B, Kunz C, Brantner P, Honigmann P, Thieringer FM. 2020.
333 Effects of Steam Sterilization on 3D Printed Biocompatible Resin Materials for Surgical
334 Guides-An Accuracy Assessment Study. *J Clin Med* 9:1506.
- 335 19. Sabino EC, Buss LF, Carvalho MPS, Prete CA, Jr., Crispim MAE, Fraiji NA, Pereira
336 RHM, Parag KV, da Silva Peixoto P, Kraemer MUG, Oikawa MK, Salomon T, Cucunuba
337 ZM, Castro MC, de Souza Santos AA, Nascimento VH, Pereira HS, Ferguson NM, Pybus
338 OG, Kucharski A, Busch MP, Dye C, Faria NR. 2021. Resurgence of COVID-19 in
339 Manaus, Brazil, despite high seroprevalence. *Lancet* 397:452-455.
- 340 20. Abdool Karim SS, de Oliveira T. 2021. New SARS-CoV-2 Variants - Clinical, Public
341 Health, and Vaccine Implications. *N Engl J Med*.

342

343

344

345

346 **FIGURE LEGENDS**

347

348 **Figure 1. In-house 3D printed swab model.** Design of the Northwell 3D swab model with the
349 addition of a breakout point (A) used to 3D-print swab in our hospital (B and C). Swabs were
350 individually packed in autoclavable and vacuum-sealed pouches (D) for sterilization. (E) Flexibility
351 was mechanically tested using semicircular canals (radius of 15, 25 and 35 mm).

352

353 **Figure 2. Validation of 3D printed swabs sterilization.** Swab heads inoculated with *G.*
354 *stearothermophilus* spore suspension before sterilization cultured in soy broth culture media.
355 Bacteria growth was assessed by measuring the optical density (O.D.) at 600nm. Culture media
356 alone was used as negative control.

357

358 **Figure 3. Cycle threshold (Ct) values of reverse-transcriptase polymerase chain reaction**
359 **(RT-PCR) for the ORF1 and E genes.** Participants were swabbed in the same nostril with a
360 flocked and a 3D printed swab, successively. RT-PCR was performed to measure the Ct values of
361 *ORF1* (A) and *E* (B) viral genes for each swab. An internal control (Ctrl) was also included (C).
362 Statistical analyses are detailed in Table 1.

363

364

365

366

367
368 **TABLE 1.** Means Ct values of samples collected from individuals tested with a flocked or a 3D
369 printed swab^a.

	Flocked mean Ct	3D mean Ct	Delta Ct	p- value
<i>ORF1</i>	26.06	26.51	0.44	0.92
<i>E</i>	28.03	28.30	0.26	0.27
<i>Ctrl</i>	35.16	35.35	0.19	0.59

370
371
372
373
374
375
376
377
378
379
380 ^aDifference between means was evaluated with the Wilcoxon matched-pairs test.

381
382

383
 384
 385 **TABLE 2.** Tables of agreement between flocked and 3D printed swabs showing positive and
 386 negative concordance percentages with Kappa values (**A**) and total number of positive (+),
 387 negative (-) and inconclusive (IC) PCR results (**B**)^b.

388
 389 **A**

		3D	3D	3D	Total
		+	-	IC	
Flocked	+	30	1		31
Flocked	-	1	31	0	32
Flocked	IC	0	0	0	0
Total		31	32	0	63

403
 404 **B**

	%	95% IC
Positive concordance	96,8	82,4 - 99,9
Negative concordance	96.9	82,9 - 99,9
Total concordance	96.8	88,5 - 99,8
Kappa value	0.936	0,738 - 0,994

415
 416 ^b IC: Confidence Interval





